The improvement of an anti-CD22 immunotoxin: Conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan

mAbs

Volumn 3, Issue 5, 2011, Pages 479-486

  Kawa, Seiji ^a   Onda, Masanori ^a   Ho, Mitchell ^a   Kreitman, Robert J ^a   Bera, Tapan K ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Affinity maturation; Alanine scan; HA22; Immunotoxin; V H V L interface

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD22; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; FERMENTATION; FLUORESCENCE ACTIVATED CELL SORTING; HEAVY CHAIN; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; LIGHT CHAIN; LYMPHOMA CELL LINE; MOLECULAR MODEL; MUTANT; POLYACRYLAMIDE GEL ELECTROPHORESIS; WILD TYPE;

ADP RIBOSE TRANSFERASES; ALANINE; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIGENS, CD22; BACTERIAL TOXINS; CELL LINE; DISULFIDES; EXOTOXINS; HUMANS; LYMPHOMA, B-CELL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; VIRULENCE FACTORS;

EID: 80052572908     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.5.17228     Document Type: Article

References (42)

1. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 9:1073-8.
2. Zhang Q, Chen G, Liu X, Qian Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res 2007; 17:89-99.
3. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6:559-65.
4. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58:221-37.
5. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJP, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23:6719-29.
6. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13:5144-9.
7. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18:1622-36.
8. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 2000; 4:1476-87.
9. Kreitman RJ, Fitzgerald DJ, Pastan I. Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma 2009; 50:32-7.
10. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002; 8:995-1002.
11. Lechleider R, Pastan I. Advances in the development of anti-CD22 immunotoxins containing Pseudomonas exotoxin for treatment of hematologic malignancies. J Cancer Sci Ther 2011; 3: Open Access (http://dx.doi. org/10.4172/1948-5956.1000057).
12. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009; 113:3792-800.
13. Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chen 2005; 280:607-17.
14. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-4.
15. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 2004; 248:503-18.
16. Rajagopal V, Pastan I, Kreitman RJ. A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs. Protein Eng 1997; 12:1453-9.
17. H. CDR3 mutation alters idiotypy and specificity. J Immunol 1991; 147:3623-31.
18. L regions of murine monoclonal antibodies against 3-fucosyllactosamine. Immunol 1988; 140:1212-7.
19. James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity. Science 2003; 299:1362-7.
20. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Structure of the extracellular region of HER2 alone and in complex with Herceptin Fab. Nature 2003; 421:756-60.
21. Kelley RF, O'Connell MP. Thermodynamic analysis an antibody functional epitope. Biochemistry 1993; 32:6828-35.
22. th Ed., National Institutes of Health Publication 91-3242, Bethesda MD 1991.
23. Lefranc MP. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res 2001; 29:207-9.
24. Yelton DE, Rosok MJ, Cruz G, Cosand WL, Bajorath J, Hellström KE, et al. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J Immunol 1995; 155:1994-2004.
25. Barbas CF, Burton DR. Selection and evolution of high affinity human anti-viral antibodies. Trends Biotechnol 1996; 14:230-4.
26. Yang WP, Green K, Pinzsweeney S, Briones AT, Burton DR, Barbas DF. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 1995; 254:392-403.
27. Low NM, Holliger P, Winter F. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J Mol Biol 1996; 260:359-68.
28. Dekruif J, Boel E, Logtenberg T. Selection and application of human single-chain Fv antibody fragments from a semisynthetic phage antibody display library with designed CDR3 regions. J Mol Biol 1995; 248:97-105.
29. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999; 17:568-72.
30. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol 1996; 255:28-43.
31. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, et al. Conformations of immunoglobulin hypervariable regions. Nature 1989; 342:877-83.
32. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927-48.
33. Ueda H, Tsumoto K, Kubota K, Suzuki E, Nagamune T, Nishimura H, et al. Open sandwich ELISA: a novel immunoassay based on the interchain interaction of antibody variable region. Nat Biotechnol 1996; 14:1714-8.
34. Sasajima Y, Iwasaki R, Tsumoto K, Kumagai I, Ihara M, Ueda H. Expression of antibody variable region-human alkaline phosphatase fusion proteins in mammalian cells. J Immunol Methods 2010; 361:57-63.
35. Hugo N, Weidenhaupt M, Beukes M, Xu B, Janson JC, Vernet T, et al. VL position 34 is a key determinant for the engineering of stable antibodies with fast dissociation rates. Protein Eng 2003; 16:381-6.
36. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997; 5:481-504.
37. Mintz U, Sachs L. Changes in the surface membrane of lymphocytes from patients with chronic lymphocytic leukemia and Hodgkin's disease. Int J Cancer 1975; 15:253-9.
38. Bannister D, Popovic B, Sridharan S, Giannotta F, Filée P, Yilmaz N, et al. Epitope mapping and key amino acid identification of anti-CD22 immunotoxin CAT-8015 using hybrid β-lactamase display. Protein Eng Des Sel 2011; 24:351-60.
39. Du X, Nagata S, Ise T, Stetler-Stevenson M, Pastan I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood 2008; 111:338-43.
40. Berridge FV, Tan AS, Herst PM. Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction. Biotechnol Annu Rev 2005; 11:127-52.
41. Benedict CA, MacKrell AJ, Anderson WF. Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods 1997; 2:223-31.
42. Krauss J, Arndt MA, Martin AC, Liu H, Rybak SM. Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment. Protein Eng 2003; 16:753-9.